Laboratorios Farmaceuticos Rovi revenue and financials
€58.65Change from previous close: +0.86%Absolute change: +€0.50
In the fiscal year ended December 2025, Laboratorios Farmaceuticos Rovi reported revenue of €743.48M (−2.65% year over year). Net income was €140.44M, a net margin of 18.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −2.65%
- 2025 vs 2024
- Net income growth
- +2.60%
- 2025 vs 2024
- Net margin
- 18.9%
- 2024: 17.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 81.3 | 13.0 | 85.7 | 73.4 | 9.2 | — |
| Depreciation and amortization | 9.8 | 8.2 | 8.2 | 7.5 | 7.5 | — |
| Capital expenditure | -22.7 | -7.7 | -29.4 | -17.6 | -12.6 | — |
| Investing cash flow | -46.3 | -7.4 | -27.0 | -17.5 | -12.4 | — |
| Financing cash flow | -5.5 | -6.2 | -7.9 | -52.7 | 19.8 | — |
| Dividends paid | — | — | 0.0 | — | — | — |
| Share repurchases | -17.8 | -21.5 | -10.1 | -16.4 | -13.7 | — |
| Debt issued | — | — | 0.0 | 1.1 | 46.5 | 0.0 |
| Debt repaid | -7.1 | -7.3 | -7.4 | -6.9 | -26.4 | — |
| Net change in cash | 29.4 | -0.6 | 50.8 | 3.1 | 16.6 | — |
| Free cash flow | 58.6 | 5.3 | 56.3 | 55.8 | -3.4 | — |